EPISODE · Oct 11, 2022 · 11 MIN
Why the U.S. lags in approving a nasal Covid vaccine
from POLITICO's Pulse Check · host POLITICO
Foreign rivals are developing nasal vaccines that could stop Covid transmission and a U.S. company invented the nasal vaccine that an Indian drugmaker licensed. But in the United States, Congress can’t agree on how to pay for additional money to fund next-generation Covid vaccines. Carmen Paun about her reporting with Megan Messerly. Plus, Dr. David Curiel on developing the nasal Covid-19 vaccine that Indian drugmaker Bharat Biotech has licensed. Learn more about your ad choices. Visit megaphone.fm/adchoices
What this episode covers
Foreign rivals are developing nasal vaccines that could stop Covid transmission and a U.S. company invented the nasal vaccine that an Indian drugmaker licensed. But in the United States, Congress can’t agree on how to pay for additional money to fund next-generation Covid vaccines. Carmen Paun about her reporting with Megan Messerly. Plus, Dr. David Curiel on developing the nasal Covid-19 vaccine that Indian drugmaker Bharat Biotech has licensed. Learn more about your ad choices. Visit megaphone.fm/adchoices
NOW PLAYING
Why the U.S. lags in approving a nasal Covid vaccine
No transcript for this episode yet
Similar Episodes
Jun 20, 2026 ·2m
Jun 20, 2026 ·2m
Jun 15, 2026 ·3m
Jun 15, 2026 ·3m
Jun 14, 2026 ·2m
Jun 14, 2026 ·2m